Dravet syndrome pipeline review 2018

Dravet syndrome pipeline and opportunities review – July 2018 is a market research publication that provides an overview of the global therapeutic landscape of Dravet syndrome, an orphan epilepsy disorder with multiple non-seizure comorbidities and high unmet medical need.

As of July 2018, the Dravet syndrome pipeline comprises 14 drug candidates, and 9 different products have received orphan drug designations. In the last 12 months the pipeline has changed by, among others, the approval by the FDA of Epidiolex (cannabidiol) by GW Pharmaceuticals for the treatment of Dravet syndrome, the announcement of positive data from two Phase III clinical trials with ZX008 from Zogenix, and the arrival of a new company pursuing a disease-modifying antisense-based approach (Stoke Therapeutics). 

The 2018 pipeline report includes the most recent updates on programs from GW Pharmaceuticals, Zogenix, PTC Therapeutics, Ovid Therapeutics, Takeda, Epygenix Therapeutics, Zynerba Pharmaceuticals, Biscayne Neurotherapeutics, Praxis Precision Medicines, Sage Therapeutics, OPKO Health, Xenon Pharmaceuticals, Stoke Therapeutics and Lundbeck. 

The Dravet syndrome pipeline and opportunities review – July 2018 report also includes an analysis of the competitive landscape, unmet needs, and evaluates current and future opportunities of the Dravet syndrome market.

The complete report as well as the tables and figures are accessible through the links below.


Dravet syndrome pipeline review 2017

Dravet syndrome is an orphan epilepsy disorder with multiple non-seizure comorbidities and high unmet medical need. In the last 5 years, Dravet syndrome has gained popularity as an orphan indication within epilepsy, and the pipeline has grown from no FDA-approved and only one drug approved by the EMA to at least 13 development programs.

Dravet syndrome pipeline and opportunities review - June 2017 is a market research publication that provides an overview of the global therapeutic landscape of Dravet syndrome.

As of June 2017, 8 different products have received orphan drug designations for Dravet syndrome, there are 3 drug candidates in late-stage placebo-controlled Phase II or III studies, and 2 of the products in development are potentially disease-modifying treatments.

The pipeline report includes the most recent updates on programs from GW Pharmaceuticals, Zogenix, PTC Therapeutics, Biscayne Neurotherapeutics, OPKO Health, Ovid Therapeutics, Takeda, Epygenix Therapeutics, INSYS Therapeutics, Xenon Pharmaceuticals, Sage Therapeutics and Lundbeck. 

The Dravet syndrome pipeline and opportunities review - June 2017 report also includes an analysis of the competitive landscape and evaluates current and future opportunities of the Dravet syndrome market.

The complete report as well as the tables and figures are accessible through the links below.

(c) 2017 Dracaena Report. This report, sections of it and figures can be copied and distributed with attribution. for noncommercial purposes only.